Found: 26
Select item for more details and to access through your institution.
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study.
- Published in:
- Clinical & Translational Gastroenterology, 2019, v. 10, n. 4, p. e00007, doi. 10.14309/ctg.0000000000000007
- By:
- Publication type:
- Article
PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease.
- Published in:
- 2017
- By:
- Publication type:
- Report
A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 556, doi. 10.1002/cpdd.883
- By:
- Publication type:
- Article
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct‐Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse‐Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 962, doi. 10.1002/cpdd.701
- By:
- Publication type:
- Article
Pharmacokinetic Interactions Between the Fixed‐Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 952, doi. 10.1002/cpdd.702
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo‐Controlled, Multiple‐Dose Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 4, p. 382, doi. 10.1002/cpdd.429
- By:
- Publication type:
- Article
Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide IB clinical probe than rosuvastatin.
- Published in:
- British Journal of Clinical Pharmacology, 2014, v. 78, n. 3, p. 587, doi. 10.1111/bcp.12377
- By:
- Publication type:
- Article
A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants.
- Published in:
- Clinical Pharmacology, 2020, v. 12, p. 1, doi. 10.2147/CPAA.S224662
- By:
- Publication type:
- Article
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 5, p. 665, doi. 10.1007/s00228-018-2585-3
- By:
- Publication type:
- Article
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 2, p. 133, doi. 10.1007/s40261-020-00974-8
- By:
- Publication type:
- Article
Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection.
- Published in:
- Clinical Infectious Diseases, 2014, v. 59, n. 12, p. 1657, doi. 10.1093/cid/ciu696
- By:
- Publication type:
- Article
Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 5, p. 1231, doi. 10.1002/cpt.3337
- By:
- Publication type:
- Article
Industrial Perspective on the Benefits Realized From the FDA's Model‐Informed Drug Development Paired Meeting Pilot Program.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 5, p. 1172, doi. 10.1002/cpt.2265
- By:
- Publication type:
- Article
Fine‐Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 6, p. 1325, doi. 10.1002/cpt.1737
- By:
- Publication type:
- Article
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
- Published in:
- European Journal of Clinical Pharmacology, 2017, v. 73, n. 5, p. 593, doi. 10.1007/s00228-017-2216-4
- By:
- Publication type:
- Article
Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression.
- Published in:
- Science Translational Medicine, 2012, v. 4, n. 148, p. 1, doi. 10.1126/scitranslmed.3003877
- By:
- Publication type:
- Article
Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single-Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 12, p. 1712, doi. 10.1177/0091270010387792
- By:
- Publication type:
- Article
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 5, p. 666, doi. 10.1002/jcph.1052
- By:
- Publication type:
- Article
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 7, p. 1753, doi. 10.1111/cts.13290
- By:
- Publication type:
- Article
Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development.
- Published in:
- CTS: Clinical & Translational Science, 2021, v. 14, n. 6, p. 2348, doi. 10.1111/cts.13099
- By:
- Publication type:
- Article
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy.
- Published in:
- CTS: Clinical & Translational Science, 2018, v. 11, n. 6, p. 562, doi. 10.1111/cts.12565
- By:
- Publication type:
- Article
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy.
- Published in:
- CTS: Clinical & Translational Science, 2018, v. 11, n. 6, p. 553, doi. 10.1111/cts.12564
- By:
- Publication type:
- Article
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
- Published in:
- Journal of Gastroenterology & Hepatology, 2019, v. 34, n. 9, p. 1597, doi. 10.1111/jgh.14636
- By:
- Publication type:
- Article